About: Institute for Neurodegenerative Disorders

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Institute for Neurodegenerative Disorders Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

nonprofit organization in New Haven, United States

Attributes	Values
rdf:type	Item
description	amerikanische Non-Profit-Organisation (de) американська неприбуткова організація (uk) nonprofit organization in New Haven, United States (en)
IRS Employer Identification Number	wds:Q30287666-43C1EA3C-9911-4B63-B7BC-F86399B1BF4C
IRS Employer Identification Number	06-1582206
rdfs:label	Institute for Neurodegenerative Disorders (en)
skos:prefLabel	Institute for Neurodegenerative Disorders (en)
name	Institute for Neurodegenerative Disorders (en)
ROR ID	wds:Q30287666-1E7D9226-3EE0-4094-B136-67ED8A852E91
ROR ID	022hrs427
instance of	wds:Q30287666-DF608EBF-23B8-4883-9D71-86B6D22D331C
instance of	nonprofit organization
country	wds:Q30287666-49013CD1-6E20-4D85-B78F-81A9D9613768
country	United States of America
inception	wds:Q30287666-1A71B9ED-0881-45E2-8B9D-B049B15FE577
inception	2001-01-01 00:00:00Z (xsd:dateTime)
skos:altLabel	IND (en)
located in the adm...erritorial entity	wds:Q30287666-02D3B41C-9CDD-4780-B594-86BEEB913F04
ISNI	wds:Q30287666-409EC8A6-D45B-4F95-AB2B-EE6BB33ACE9F
coordinate location	wds:Q30287666-5E1310FB-AAE0-4220-8B5C-2B0817D36D7D
official website	wds:Q30287666-52EE269D-2467-4437-856E-2DFC5953FCD7
located in the adm...erritorial entity	New Haven
ISNI	0000000459133633
coordinate location	POINT(-72.929659 41.304236)
official website	http://www.indd.org/
GRID ID	wds:Q30287666-E3252DF7-F020-4F38-A1A8-9D48F0DA4C36
GRID ID	grid.429091.7
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q30287666
is cites work of	A genetical study of the oraons of the Chota Nagpur plateau (Bihar, India) Fermentative production of fodder yeasts
is cites work of	wds:Q39792162-B9A6105F-5040-46F6-9922-D70709D8D67F wds:Q76485953-A66684BF-D426-423F-8576-7407174010E8
is research site of	Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558 Development of Cognitive Assessment Tools in Parkinson Disease Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513 Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition Prospective Huntington At Risk Observational Study Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease Systemic Synuclein Sampling Study (S4) Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC The Study of the Impact of Disclosing Imaging Study Information to Trial Participants Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease Safety of Urate Elevation in Parkinson's Disease An Open-Label Crenezumab Study in Patients With Alzheimer's Disease Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions Parkinson's Research: The Organized Genetics Initiative Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™ Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD) Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
is research site of	wds:Q61980636-0AE549C4-CE18-4E43-A9E5-8B16BC3059BA wds:Q63576117-C1F51D6A-41A4-490F-8446-D3A3DC438F6C wds:Q63818349-60256B04-4D10-45B4-9946-8D72FE3BED5A

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software